drugset / Trial / NCT02403544
Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma
Phase 1
Unknown
30 enrolled
Chinese Academy of Medical Sciences
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · collabSanofi · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I study to evaluate the safety of concurrent chemoradiation combining radiotherapy (IGRT) with two cytotoxic agents, capecitabine and oxaliplatin in patients with advanced or inoperable hepatocellular carcinoma.
Timeline
- Start
- 2013-09
- Primary completion
- 2016-06
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 600 mg/m2 | Oral |
| Subject | Oxaliplatin | Small molecule | 30 mg/m2 | Intravenous |